Human PD-L2 (CD273) antibody - Clone 24F.10C12

Recombinant anti-human PD-L2 - For Bio IC™ assay and detection

Anti-hPD-L2 blocks PD-1/PD-L2 axis

Anti-hPD-L2-mIgG2a is a recombinant monoclonal antibody (mAb) designed for use with PD-1/PD-L2 cellular assays to study immune checkpoint (IC) modulation. This mAb is derived from the 24F.10C12 clone, targeting the human programmed death ligand 2 (hPD-L2, aka CD273).

 More details

Anti-hPD-L2-mIgG2a can be used as a benchmark antibody in our PD-1/PD-L2 Bio IC™ cellular assay, which is designed to screen antagonists, such as antibodies, Fc-fusion proteins, or small molecules, targeting the PD-1/PD-L2 axis. In addition, it is suitable for use in flow cytometry (see figures).

Key features

• Each lot is functionally tested and validated
• The complete sequence of the antibody construct has been verified
• Absence of endotoxins determined by the EndotoxDetect™ assay

InvivoGen’s products are for research use only, and not for clinical or veterinary use.

Figures

Activation of Jurkat-Lucia™ TCR-hPD-1 cells using Anti-hPD-L2 mAb. Raji-APC-hPD-L2 and Jurkat-Lucia™ TCR-hPD-1 cells were incubated with gradient concentrations of Anti-hPD-L2-mIgG2a for 24 hours. NFAT activation, reflecting the disruption of PD-1/PD-L2 inhibitory interaction, was assessed by determining Lucia luciferase activity in the supernatant using QUANTI-Luc™. The fold increase over non-induced cells (no mAbs) is shown.

Cell surface staining of human PD-L2. Raji‑APC-hPD-L2 cells were incubated with Anti-mPD-L2-mIgG2a or and isotype control for 1h at 4°C. Subsequently, a secondary PE-labeled antibody was added and incubated at 4°C for 30 minutes. Cell surface staining was analyzed by flow cytometry.

Specification

Application: PD-1/PD-L2 Bio IC™ assay, flow cytometry

Isotype:  Mouse IgG2a, kappa

Recommended isotype control: Mouse IgG2a

Target: Human PD-L2, CD273

Species reactivity: Human

Clone: 24F.10C12

Source: CHO cells 

Purification: Protein A

Molecular weight: 145 kDa

Physical form: Lyophilized

Formulation buffer: Sodium phosphate buffer with glycine, saccharose, and stabilizing agents

Reconstitution buffer: Sterile water (not provided)

Purity: ≥ 95 %

Quality control: Each lot is functionally tested and validated.

Contents

Anti-hPD-L2-mIgG2a purified monoclonal antibody is provided lyophilized. It is available in two quantities:

• hpdl2-mab10​: 100 µg
• hpdl2-mab10-03: 3 x 100 µg

 The product is shipped at room temperature.

 Upon receipt, store lyophilized antibody at -20 °C.

 Lyophilized product is stable for at least 1 year.

 Avoid repeated freeze-thaw cycles.

Details

Programmed cell death ligand 2 (PD-L2), also known as cluster of differentiation 273 (CD273) or B7-DC, is a transmembrane protein that is mostly expressed by antigen-presenting cells, such as dendritic cells and macrophages [1]. It serves as a second ligand for programmed cell death protein 1 (PD-1), complementing PD-L1 in mediating peripheral immune tolerance and maintaining immune homeostasis during infection [1, 2].

When PD-L2 binds to PD-1 on T cells, it inhibits T cell receptor (TCR) signaling, reduces cytokine production, and limits T cell proliferation—mechanisms essential for preventing excessive immune activation. Like PD-L1, PD-L2 is also co-opted by cancer cells and tumor-associated immune cells to suppress T cell-dependent anti-tumor immunity [2,3]. 

Elevated PD-L2 expression has been observed in various malignancies, including lung, colorectal, as well as breast cancers, and is often associated with poor prognosis [4]. The continuous exploration of the clinical application of PD-L2 has brought exciting prospects for promoting cancer treatment, including small molecules, PD-L2-specific vaccines, and monoclonal antibodies (mAbs) [4]. However, the clinical approval of PD-L2-specific therapeutics for tumor treatment remains elusive, necessitating further investigation and discovery [4].

References

1. Latchman, Y. et al. 2001. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2, 261–268.
2. Yearley, J.H. et al. 2017. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Clin Cancer Res 23, 3158–3167.
3. Rozali, E.N. et al. 2012. Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol 2012, 656340.
4. Yang Y, et al. 2024. Programmed cell death-ligand 2: new insights in cancer. Front Immunol. 2024 Mar 28;15:1359532.